Shemesh Colby S, Moshkelani Delaram, Zhang Hailing
Drug Delivery Laboratory, Department of Pharmaceutical Sciences College of Pharmacy, Mercer University, 3001 Mercer University Drive, Atlanta, Georgia, 30341, USA.
Pharm Res. 2015 May;32(5):1604-14. doi: 10.1007/s11095-014-1560-7. Epub 2014 Nov 19.
The focus of this research was to formulate and evaluate a theranostic liposomal delivery system using indocyanine green (ICG) as a photosensitizer, triggered by near infrared (NIR) irradiation, for in vivo photodynamic therapy (PDT) of breast cancer.
Cytotoxicity of PDT using liposomal ICG (LPICG) as well as free ICG (FRICG) was evaluated in the human MDA-MB-468 triple-negative breast cancer (TNBC) cell line. NIR irradiation-induced increase in temperature was also monitored both in vitro and in vivo. Quantitative pharmacokinetic profile and fluorescence imaging-based biodistribution patterns of both formulations were obtained using the human TNBC xenograft model in nude mice. Overall safety, tolerability, and long-term anti-tumor efficacy of LPICG versus FRICG-mediated PDT was evaluated.
Significant loss of cell viability was achieved following photoactivation of LPICG via NIR irradiation. Temperatures of irradiated LPICG increased with increasing concentrations of loaded ICG, which correlated with significant rise of temperature compared to PBS in vivo (p < 0.01). Pharmacokinetic assessment revealed a significant increase in systemic distribution and circulation half-life of LPICG, and NIR fluorescence imaging demonstrated enhanced accumulation of liposomes within the tumor region. Tumor growth in mice treated with LPICG followed by NIR irradiation was significantly reduced compared to those treated with FRICG, saline, and irradiation alone.
In vivo photodynamic therapy using LPICG demonstrated targeted biodistribution and superior anti-tumor efficacy in a human TNBC xenograft model compared to FRICG. In addition, this unique delivery system exhibited a promising role in NIR image-guided delivery and real-time biodistribution monitoring of formulation with ICG serving as the fluorescent probe.
本研究的重点是制备并评估一种治疗诊断用脂质体递送系统,该系统使用吲哚菁绿(ICG)作为光敏剂,由近红外(NIR)照射触发,用于乳腺癌的体内光动力疗法(PDT)。
在人MDA-MB-468三阴性乳腺癌(TNBC)细胞系中评估使用脂质体ICG(LPICG)以及游离ICG(FRICG)进行PDT的细胞毒性。还在体外和体内监测NIR照射引起的温度升高。使用人TNBC裸鼠异种移植模型获得两种制剂的定量药代动力学概况和基于荧光成像的生物分布模式。评估了LPICG与FRICG介导的PDT的总体安全性、耐受性和长期抗肿瘤疗效。
通过NIR照射对LPICG进行光激活后,细胞活力显著丧失。照射的LPICG的温度随着负载ICG浓度的增加而升高,这与体内与PBS相比温度的显著升高相关(p < 0.01)。药代动力学评估显示LPICG的全身分布和循环半衰期显著增加,并且NIR荧光成像表明脂质体在肿瘤区域内的积累增强。与单独用FRICG、盐水和照射治疗的小鼠相比,用LPICG然后进行NIR照射治疗的小鼠的肿瘤生长显著减少。
在人TNBC异种移植模型中,与FRICG相比,使用LPICG进行体内光动力疗法显示出靶向生物分布和优异的抗肿瘤疗效。此外,这种独特的递送系统在以ICG作为荧光探针的制剂的NIR图像引导递送和实时生物分布监测中发挥了有前景的作用。